Cargando…
Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine
Metformin is a common co‐medication for many diseases and the victim of clinical drug‐drug interactions (DDIs) perpetrated by cimetidine, trimethoprim and pyrimethamine, resulting in decreased active renal clearance due to inhibition of organic cation transport proteins and increased plasma exposure...
Autores principales: | Elsby, Robert, Chidlaw, Stephen, Outteridge, Samuel, Pickering, Sarah, Radcliffe, Amy, Sullivan, Rebecca, Jones, Hayley, Butler, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625161/ https://www.ncbi.nlm.nih.gov/pubmed/28971610 http://dx.doi.org/10.1002/prp2.357 |
Ejemplares similares
-
Differences in Coformer Interactions of the 2,4-Diaminopyrimidines
Pyrimethamine and Trimethoprim
por: Alaa Eldin Refat, Lamis, et al.
Publicado: (2022) -
Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3
por: Elsby, Robert, et al.
Publicado: (2023) -
Cimetidine and therapy of rodent tumours.
por: Hannant, D., et al.
Publicado: (1982) -
Cimetidine in the Treatment of Herpes Zoster
por: Levy, D. W., et al.
Publicado: (1985) -
Cimetidine enhancement of cyclophosphamide antitumour activity.
por: Dorr, R. T., et al.
Publicado: (1982)